4-(1-hydroxycyclobutyl)benzonitrile | 214759-68-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-hydroxycyclobutyl)benzonitrile
• CAS: 214759-68-9
• 化学式: C₁₁H₁₁NO
• 分子量: 173.214
• InChiKey: YBCRWEVBAAPJLE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(1-hydroxycyclobutyl)benzonitrile 在 2,2'-联吡啶 、 manganese(II) triflate 、 叠氮基三甲基硅烷 、 tetrabutylammonium tetrafluoroborate 作用下， 以 水 、 乙腈 为溶剂， 以37 %的产率得到4-(4-azidobutanoyl)benzonitrile
  参考文献：
  名称：

  锰介导的环丁醇衍生物与 TMSN3 的电氧化开环叠氮化反应

  摘要：

  已开发出叔环丁醇的锰电催化开环叠氮化反应。该区域选择性方法适用于多种环丁醇的叠氮化，在无化学氧化剂的反应条件下以 23-91% 的产率提供 γ-叠氮酮。详细的机理研究表明，Mn介导的烷氧基自由基生成，随后β-断裂形成以碳为中心的自由基物质的过程可能参与了这种转变。

  DOI：

  10.1002/adsc.202400101
• 作为产物：
  描述：

  环丁酮 、 4-溴苯腈 在 lithium chloro-isopropyl-magnesium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 以40%的产率得到4-(1-hydroxycyclobutyl)benzonitrile
  参考文献：
  名称：

  锰催化的烷氧基自由基对环烷醇的电化学解构氯化反应。

  摘要：

  已经开发了锰催化的环烷醇的电化学解构氯化法。这种电化学方法可从醇中获得烷氧基，并具有广泛的底物范围，可将各种环丙醇和环丁醇转化为可合成使用的β-和γ-氯化酮（40个实例）。此外，采用循环流电化学和连续在线纯化的组合以克为单位获得产物。

  DOI：

  10.1021/acs.orglett.9b03652

文献信息

• HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20110301122A1

  公开（公告）日：2011-12-08

  The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及新型取代芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Aryl compounds with aminoalkyl substituents and their use
  申请人：Härter Michael

  公开号：US20110312930A1

  公开（公告）日：2011-12-22

  The present application relates to novel aryl compounds with aminoalkyl substituents, to processes for their preparation, to their use for treatment and/or prevention of diseases and to their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有氨基烷基取代基的新型芳基化合物，涉及其制备方法，涉及它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应低氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步的治疗措施结合使用。
• Substituted heterocyclylbenzylpyrazoles and use thereof
  申请人：HÄRTER Michael

  公开号：US20120028950A1

  公开（公告）日：2012-02-02

  The present application relates to novel substituted 1-[3-(heterocyclyl)benzyl]-1H-pyrazole derivatives, to processes for preparation thereof, to use thereof for treatment and/or prevention of diseases and to use thereof for production of medicaments for treatment and/or prevention of diseases, more particularly for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be effected in the form of monotherapy or else in combination with other medicaments or further therapeutic measures.

  本申请涉及新颖的取代的1-[3-(杂环基)苄基]-1H-吡唑衍生物，其制备方法，用于治疗和/或预防疾病以及用于生产治疗和/或预防疾病的药物的用途，更具体地用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以以单药疗法形式进行，也可以与其他药物或进一步的治疗措施结合使用。
• HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS
  申请人：Härter Michael

  公开号：US20130196964A1

  公开（公告）日：2013-08-01

  The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

  本申请涉及具有杂环取代基的新型芳基化合物，其制备方法，它们用于治疗和/或预防疾病以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防过度增殖和血管生成性疾病以及那些由于代谢适应缺氧状态而引起的疾病。这种治疗可以作为单独治疗进行，也可以与其他药物或进一步治疗措施结合使用。
• Pyrrolyl-and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
  申请人：Marfat Anthony

  公开号：US06869945B2

  公开（公告）日：2005-03-22

  This application is directed to compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: where Y is ═C(R 1 a )— or —[N→(O) k ]— where k is 0 or 1; G 1 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic, or that is a 7- to 12-membered, fused polycyclic; provided that G 1 is not a discontinuous or restricted biaryl moiety as defined under G 2 ; where optionally one carbon atom may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; -G 2 is a saturated or unsaturated carbon ring system that is a 3- to 7-membered monocyclic; or that is a 7- to 12-membered, fused polycyclic; or that is a 7- to 18-membered discontinuous or restricted biaryl moiety; wherein for each of the carbon ring systems recited, optionally one carbon atom of said carbon ring system may be replaced by a heteroatom selected from N, O, and S; where optionally a second carbon atom thereof, and further optionally a third carbon atom thereof may be replaced by N; E is selected from: and all other substituents shown above are as defined in the specification.

  本申请涉及一种化合物，其可用作PDE4的抑制剂，用于治疗由嗜酸性粒细胞的激活和脱颗粒调节的疾病，特别是哮喘、慢性支气管炎和慢性阻塞性肺疾病，其化学式为：其中Y为═C（R1a）—或—[N→（O）k]—，其中k为0或1；G1为饱和或不饱和的碳环系统，是一个3-至7-成员的单环，或是一个7-至12-成员的融合多环；前提是G1不是根据G2下定义的不连续或受限制的双芳基基团；其中可选地，一个碳原子可被N、O和S中选择的一个杂原子所替换；其中可选地，其第二个碳原子，进一步可选地，其第三个碳原子可被N所替换；-G2为饱和或不饱和的碳环系统，是一个3-至7-成员的单环；或是一个7-至12-成员的融合多环；或是一个7-至18-成员的不连续或受限制的双芳基基团；其中对于所述的每个碳环系统，可选地，其一个碳原子可被N、O和S中选择的一个杂原子所替换；其中可选地，其第二个碳原子，进一步可选地，其第三个碳原子可被N所替换；E选择自：以及上述所有其他取代基在规范中定义。